Significance of TP53 mutations as predictive markers of adjuvant cisplatin‐based chemotherapy in completely resected non‐small‐cell lung cancer. Issue 3 (15th January 2014)

• Record Type: Journal Article
• Authors: Ma, Xiaoli; Rousseau, Vanessa; Sun, Haiji; Lantuejoul, Sylvie; Filipits, Martin; Pirker, Robert; Popper, Helmut; Mendiboure, Jean; Vataire, Anne-Lise; Le Chevalier, Thierry; Soria, Jean Charles; Brambilla, Elisabeth; Dunant, Ariane; Hainaut, Pierre
• Is Part Of: Molecular oncology. Volume 8:Issue 3(2014:May)
• Page Start: 555
• Page End: 564
• Publication Date: 2014-01-15
• Subjects: TP53 -- Mutations -- NSCLC -- Chemotherapy -- Cisplatin -- Randomized trial; Cancer -- Molecular aspects -- Periodicals; 616.994005
• DOI: 10.1016/j.molonc.2013.12.015
• Languages: English
• ISSNs: 1574-7891

Abstract

Abstract : Adjuvant cisplatin‐based chemotherapy only marginally improves survival in patients with completely resected non‐small‐cell lung cancer (NSCLC). We have evaluated the predictive value of mutations in TP53, encoding the tumour suppressor p53, in the International Adjuvant Lung Cancer Trial (IALT), a randomized trial of adjuvant cisplatin‐based chemotherapy against observation. TP53 (exons 4–8) was sequenced in 524 archived specimens of IALT patients with a median follow‐up of 7.5 years. Predictive analyses were based on Cox models adjusted for clinical and pathological variables. P‐values ≤0.01 were considered as significant. Mutations were detected in 221 patients (42%) and had no predictive value for the effect of chemotherapy (interaction between TP53 and treatment: p = 0.17 for Overall Survival (OS); p = 0.06 for Disease‐Free Interval, (DFS)). However, among patients with mutations, outcome appeared worse in treatment compared to observation arms (HR for OS = 1.36 (95% CI [0.97–1.31), p = 0.08; DFS = 1.40 (95% CI [1.01–1.95]), p = 0.04). When grouping mutations into classes according to predicted effects on protein structure, the tendency towards worse outcomes was restricted to "structure" mutations affecting residues of the hydrophobic core that are not located at the p53 protein‐DNA interface (HR for death in this class vs wild‐type T53 = 1.66; 95% CI [1.10–2.52], p = 0.02). Overall, TP53 mutations are not significant predictors of outcome in this trial of cisplatin‐based chemotherapy, although a specific class of structural mutations may be associated with a tendency towards worse outcomes upon treatment. Highlights: Chemotherapy only marginally improves survival in non‐small‐cell lung cancer. In a large randomized trial, TP53 mutation does not predict survival. Patients with mutations have worse survival in treatment than observation. A class of structural mutations may carry a detrimental effect upon treatment.